. 2022 Apr 27;7(3):100430. doi: 10.1016/j.esmoop.2022.100430

Table 2.

Univariate analysis of the association between clinical factors and patient survival

Variable	Categories	PFS		OS
Variable	Categories	HR	P-value	HR	P-value
Sex	Male versus female	1.315	0.148	1.443	0.048
Age	Above median	0.608	0.010	0.668	0.032
Tumour type	NSCLC versus melanoma	0.861	0.432	0.691	0.046
Clinical trial participation	Yes versus no	1.113	0.614	0.735	0.148
Number of metastatic sites	2 versus 0/1	0.948	0.843	0.983	0.947
Number of metastatic sites	3+ versus 0/1	1.431	0.175	1.275	0.332
Brain metastases	Yes versus no	1.428	0.105	1.757	0.007
Previous treatment	1 versus 0	0.770	0.291	1.071	0.766
Previous treatment	2+ versus 0	1.276	0.395	1.364	0.272
ECOG performance status	1 versus 0	1.701	0.029	1.429	0.152
ECOG performance status	2+ versus 0	2.253	0.002	2.524	<0.001
Comorbidities	Yes versus no	0.717	0.079	0.981	0.918
LDH	Continuous, log2	1.430	<0.001	1.373	<0.001
Use of antibiotics	yes versus no	1.661	0.009	1.533	0.025
Cumulative use	Single versus no	1.894	0.011	1.969	0.006
Cumulative use	cumulative versus no	1.495	0.103	1.454	0.124

Variables listed in bold and underlined had P-values <0.1 and were selected for subsequent multivariate analysis.

ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; LDH, lactate dehydrogenase; NSCLC, non-small-cell lung cancer; OS, overall survival; PFS, progression-free survival.